Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. reiterated a buy rating on shares of MorphoSys in a research note on Thursday, March 19th. Independent Research set a €119.00 ($138.37) price objective on shares of MorphoSys and gave the company a buy rating in a research note on Monday. Goldman Sachs Group reissued a neutral rating on shares of MorphoSys in a research report on Wednesday, January 22nd. Berenberg Bank set a €150.00 ($174.42) target price on shares of MorphoSys and gave the company a buy rating in a research report on Monday. Finally, Royal Bank of Canada set a €130.00 ($151.16) target price on shares of MorphoSys and gave the company a buy rating in a research report on Thursday, March 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of €122.88 ($142.88).
ETR MOR opened at €91.65 ($106.57) on Tuesday. The company has a debt-to-equity ratio of 9.78, a quick ratio of 7.63 and a current ratio of 7.80. The firm’s 50 day moving average price is €99.88 and its 200-day moving average price is €108.17. MorphoSys has a 52-week low of €79.70 ($92.67) and a 52-week high of €146.30 ($170.12). The company has a market cap of $3.06 billion and a PE ratio of -30.13.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
See Also: Initial Public Offering (IPO)
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.